[(3R)-3-hydroxy-2,2-dimethyl-4-[[3-(2-methylsulfanylethylamino)-3-oxopropyl]amino]-4-oxobutyl] (3Z,6Z,9Z,12Z,15Z,18Z)-henicosa-3,6,9,12,15,18-hexaenoate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: [(3R)-3-hydroxy-2,2-dimethyl-4-[[3-(2-methylsulfanylethylamino)-3-oxopropyl]amino]-4-oxobutyl] (3Z,6Z,9Z,12Z,15Z,18Z)-henicosa-3,6,9,12,15,18-hexaenoate
• 化学式: C₃₃H₅₂N₂O₅S
• 分子量: 588.8
• InChiKey: WMPXYPYRYZGWJX-SHTDOVBQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  41
• 可旋转键数：
  24
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  130
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME<br/>[FR] COMPOSITIONS ET PROCÉDÉS POUR LE TRAITEMENT DU SYNDROME DU CÔLON IRRITABLE
  申请人：CELLIX BIO PRIVATE LTD

  公开号：WO2018029545A1

  公开（公告）日：2018-02-15

  The disclosures herein provide compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX, formula X, formula XI, formula XII, formula XIII, formula XIV and formula XV or its pharmaceutical acceptable salts, as well as polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral administration, suppository, transdermal, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of irritable bowel syndrome (IBS), inflammatory bowel diseases or its associated complications.

  本公开提供化合物的公式I、公式II、公式III、公式IV、公式V、公式VI、公式VII、公式VIII、公式IX、公式X、公式XI、公式XII、公式XIII、公式XIV和公式XV，或其药用可接受盐，以及其多型、对映体、立体异构体、溶剂合物和水合物。这些盐可以制成药物组合物。药物组合物可以制成口服、栓剂、经皮、颊部、直肠、局部、经皮、经粘膜、静脉、全身、糖浆或注射用药物。这些组合物可用于治疗肠易激综合征（IBS）、炎症性肠病或其相关并发症。
• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND INFLAMMATION<br/>[FR] COMPOSITIONS ET PROCÉDÉS POUR LE TRAITEMENT DE MALADIES NEUROLOGIQUES ET D'UNE INFLAMMATION
  申请人：KANDULA MAHESH

  公开号：WO2014115098A1

  公开（公告）日：2014-07-31

  The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I; and methods for treating or preventing neurological diseases and inflammation, a neurological disease, allergy, respiratory diseases or inflammatory disorder may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of muscle disorders, neurological diseases and inflammation, spasticity, neuropathic pain, fibromyalgia, Parkinson's disease, allergy, asthma, chronic obstructive pulmonary disease, allergic rhinitis, headache, chronic pain, sub-chronic pain and local pain or its associated complications.

  该发明涉及具有化学式I或其药用可接受的盐的化合物，以及其多型、溶剂合物、对映体、立体异构体和水合物。包括化学式I化合物的有效量的药物组合物；以及用于治疗或预防神经系统疾病和炎症、神经系统疾病、过敏、呼吸系统疾病或炎症性疾病的方法，可以制备用于口服、颊内、直肠、局部、经皮、经粘膜、静脉内、肠道、糖浆或注射的药物组合物。这些组合物可以用于治疗肌肉障碍、神经系统疾病和炎症、痉挛、神经病性疼痛、纤维肌痛、帕金森病、过敏、哮喘、慢性阻塞性肺病、过敏性鼻炎、头痛、慢性疼痛、亚慢性疼痛和局部疼痛或其相关并发症的治疗。
• [EN] COMPOSITIONS AND METHODS OF FOR THE TREATMENT OF MULTIPLE SCLEROSIS AND NEURODEGENERATIVE DISEASES<br/>[FR] COMPOSITIONS ET MÉTHODES POUR LE TRAITEMENT DE LA SCLÉROSE EN PLAQUES ET DE MALADIES NEURODÉGÉNÉRATIVES
  申请人：KANDULA MAHESH

  公开号：WO2014060942A2

  公开（公告）日：2014-04-24

  The disclosures herein provide aminoacid derivatives containing therapeutic copolymer of formula I or its pharmaceutical acceptable salts, as well as polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral administration, intravenous, subdermal, transdermal administration, or injection. Such compositions aminoacid derivatives containing therapeutic copolymer may be used to treatment of multiple sclerosis and neurodegenerative diseases or its associated complications.
• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGIC DISEASES AND NEUROLOGICAL DISORDERS<br/>[FR] COMPOSITIONS ET MÉTHODES POUR LE TRAITEMENT DE MALADIES NEUROLOGIQUES ET DE TROUBLES NEUROLOGIQUES
  申请人：KANDULA MAHESH

  公开号：WO2014068460A2

  公开（公告）日：2014-05-08

  The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II; and methods for treating or preventing neurologic diseases and neurological disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of partial-onset seizures, infantile spasm, mixed seizure types of Lennox-Gastaut syndrome, myoclonic, generalized tonic clonic seizure, epilepsy, Parkinson's, obesity, migraines and bipolar depression.
• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF AUTOIMMUNE DISEASES<br/>[FR] COMPOSITIONS ET PROCÉDÉS POUR LE TRAITEMENT DE MALADIES AUTOIMMUNES
  申请人：KANDULA MAHESH

  公开号：WO2014068506A2

  公开（公告）日：2014-05-08

  The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II; and methods for treating or preventing autoimmune diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of rheumatoid arthritis, Crohn's disease, multiple sclerosis, systemic lupus erythematosus, dermatitis, ulcerative colitis, inflammatory bowel disease and other immune system related diseases.